Found: 17
Select item for more details and to access through your institution.
Correction: Integrative Omics Analysis of Rheumatoid Arthritis Identifies Non-Obvious Therapeutic Targets.
- Published in:
- PLoS ONE, 2015, v. 10, n. 8, p. 1, doi. 10.1371/journal.pone.0136334
- By:
- Publication type:
- Article
Integrative Omics Analysis of Rheumatoid Arthritis Identifies Non-Obvious Therapeutic Targets.
- Published in:
- PLoS ONE, 2015, v. 10, n. 4, p. 1, doi. 10.1371/journal.pone.0124254
- By:
- Publication type:
- Article
Exposure‐response relationships for the efficacy and safety of filgotinib and its metabolite GS‐829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies.
- Published in:
- British Journal of Clinical Pharmacology, 2022, v. 88, n. 7, p. 3211, doi. 10.1111/bcp.15239
- By:
- Publication type:
- Article
Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis.
- Published in:
- Immunological Reviews, 2010, v. 233, n. 1, p. 233, doi. 10.1111/j.0105-2896.2009.00859.x
- By:
- Publication type:
- Article
The formation and functions of the 21- and 23-kDa tyrosine-phosphorylated TCRζ subunits.
- Published in:
- Immunological Reviews, 2003, v. 191, n. 1, p. 47, doi. 10.1034/j.1600-065X.2003.00003.x
- By:
- Publication type:
- Article
086 Safety and efficacy of filgotinib in a phase 3 trial of patients with active rheumatoid arthritis and inadequate response or intolerance to biologic disease modifying anti-rheumatic drugs.
- Published in:
- 2019
- By:
- Publication type:
- Abstract
Targeting phosphatase-dependent proteoglycan switch for rheumatoid arthritis therapy.
- Published in:
- Science Translational Medicine, 2015, v. 7, n. 288, p. 1, doi. 10.1126/scitranslmed.aaa4616
- By:
- Publication type:
- Article
Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX: FINCH 1 52-week results and FINCH 4 48-week results.
- Published in:
- Modern Rheumatology, 2023, v. 33, n. 4, p. 668, doi. 10.1093/mr/roac084
- By:
- Publication type:
- Article
Long-term safety and efficacy of filgotinib treatment for rheumatoid arthritis in Japanese patients naïve to MTX treatment (FINCH 3).
- Published in:
- Modern Rheumatology, 2023, v. 33, n. 4, p. 657, doi. 10.1093/mr/roac083
- By:
- Publication type:
- Article
Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5 years.
- Published in:
- Modern Rheumatology, 2023, v. 33, n. 1, p. 64, doi. 10.1093/mr/roac020
- By:
- Publication type:
- Article
Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).
- Published in:
- Modern Rheumatology, 2022, v. 32, n. 2, p. 273, doi. 10.1093/mr/roab021
- By:
- Publication type:
- Article
Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1).
- Published in:
- Modern Rheumatology, 2022, v. 32, n. 2, p. 263, doi. 10.1093/mr/roab030
- By:
- Publication type:
- Article
Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2).
- Published in:
- Modern Rheumatology, 2022, v. 32, n. 1, p. 59, doi. 10.1080/14397595.2020.1859675
- By:
- Publication type:
- Article
Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials.
- Published in:
- Rheumatology & Therapy, 2023, v. 10, n. 1, p. 161, doi. 10.1007/s40744-022-00503-3
- By:
- Publication type:
- Article
Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study.
- Published in:
- Rheumatology & Therapy, 2023, v. 10, n. 1, p. 53, doi. 10.1007/s40744-022-00498-x
- By:
- Publication type:
- Article